CA2924360C — Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Assigned to Novartis AG · Expires 2022-04-26 · 4y expired
What this patent protects
The application relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents, and for the treatment of various disease states of prostate cancer. The application describes new agaits that target PSMA, including compounds of Formulae (l…
USPTO Abstract
The application relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents, and for the treatment of various disease states of prostate cancer. The application describes new agaits that target PSMA, including compounds of Formulae (la) or (lb), which have improved efficacy in diagnosing and treating various disease states of prostate cancer:
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.